Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2993215 | 0.98 | MEN1 (0.41) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL25362418 | 0.95 | MEN1 (0.40) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL13255991 | 0.93 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL1219462 | 0.91 | MEN1 (0.47) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL1219035 | 0.91 | MEN1 (0.47) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL15324343 | 0.91 | MEN1 (0.47) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL1219710 | 0.91 | MEN1 (0.47) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL15323525 | 0.88 | MEN1 (0.53) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL1217990 | 0.88 | MEN1 (0.53) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B | |
| SCHEMBL1219357 | 0.86 | MEN1 (0.54) | SMN1; SMN2MEN1APAF1NPC1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079534-A1 | METHOD, CELL, AND ELECTROLYTE FOR DINITROGEN CONVERSION | MONASH UNIVERSITY (AU) | 2021-03-18 | — | — | US | claimed |
| EP-3431528-B1 | METHODS AND COMPOSITIONS FOR CURING A SURFACE OF AN UNCURED POLYSULFIDE RUBBER | BOEING CO (US) | 2020-09-02 | — | — | EP | claimed |
| EP-3658505-A1 | METHOD, CELL AND ELECTROLYTE FOR DINITROGEN CONVERSION | Monash University (AU) | 2020-06-03 | — | — | EP | claimed |
| CN-110869319-A | Method for dinitrogen conversion, battery and electrolyte | 莫纳什大学 | 2020-03-06 | — | — | CN | claimed |
| EP-1954680-B1 | IONIC LIQUIDS | DU PONT (US) | 2012-05-23 | — | — | EP | claimed |
| EP-1940914-B1 | PREPARATION OF POLYTRIMETHYLENE ETHER GLYCOL AND COPOLYMERS THEREOF | DU PONT (US) | 2009-05-13 | — | — | EP | claimed |
| JP-2009511434-A | — | — | 2009-03-19 | — | — | JP | claimed |
| EP-1954658-A1 | ALKYLATION OF AROMATIC COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1954680-A1 | IONIC LIQUIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1940914-A2 | PREPARATION OF POLYTRIMETHYLENE ETHER GLYCOL AND COPOLYMERS THEREOF | E.I.Du pont de nemours and company (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007038360-A2 | PREPARATION OF POLYTRIMETHYLENE ETHER GLYCOL AND COPOLYMERS THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-04-05 | — | — | WO | claimed |
| EP-1742663-A2 | COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER | Chiasma, Ltd. (IL) | 2007-01-17 | — | — | EP | claimed |
| US-20060251713-A1 | Amino acid sequences capable of facilitating penetration across a biological barrier | CHIASMA, INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006097793-A2 | COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER | CHIASMA, LTD. (IL) | 2006-09-21 | — | — | WO | claimed |
| EP-1670500-A2 | COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER | Chiasma, Ltd. (IL) | 2006-06-21 | — | — | EP | claimed |
| US-20050232981-A1 | Compositions capable of facilitating penetration across a biological barrier | CHIASMA, INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005094785-A2 | COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER | CHIASMA, LTD. (IL) | 2005-10-13 | — | — | WO | claimed |
| US-20050136103-A1 | Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation | CHIASMA, INC. | 2005-06-23 | — | — | US | claimed |
| US-20050058702-A1 | Compositions capable of facilitating penetration across a biological barrier | CHIASMA, INC. | 2005-03-17 | — | — | US | claimed |
| US-20040146549-A1 | Amino acid sequences capable of facilitating penetration across a biological barrier | CHIASMA, INC. | 2004-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251713-A1 | Amino acid sequences capable of facilitating penetration across a biological barrier | SLC7A1, SLC1A5, SLC3A2 | SMN1; SMN2 1270/4885MEN1 2096/4885APAF1 787/4885 |
| US-20050136103-A1 | Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation | CFTR, SLC47A1, SLC47A2 | SMN1; SMN2 1654/4885MEN1 1463/4885APAF1 1149/4885 |
| US-20050232981-A1 | Compositions capable of facilitating penetration across a biological barrier | MMP8, PGF, AQP1 | SMN1; SMN2 1565/4885MEN1 2141/4885APAF1 481/4885 |
| US-20040146549-A1 | Amino acid sequences capable of facilitating penetration across a biological barrier | SLC7A1, SLC1A5, SLC3A2 | SMN1; SMN2 1270/4885MEN1 2096/4885APAF1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.